KR101671452B1 - 항rsv g 단백질 항체 - Google Patents

항rsv g 단백질 항체 Download PDF

Info

Publication number
KR101671452B1
KR101671452B1 KR1020107011433A KR20107011433A KR101671452B1 KR 101671452 B1 KR101671452 B1 KR 101671452B1 KR 1020107011433 A KR1020107011433 A KR 1020107011433A KR 20107011433 A KR20107011433 A KR 20107011433A KR 101671452 B1 KR101671452 B1 KR 101671452B1
Authority
KR
South Korea
Prior art keywords
seq
ser
positions
region consisting
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107011433A
Other languages
English (en)
Korean (ko)
Other versions
KR20100091195A (ko
Inventor
로렌스 엠. 카우바
엘렌 제이. 콜라리니
브루스 키이트
오리트 푸어드
Original Assignee
트렐리스 바이오싸이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트렐리스 바이오싸이언스 인코포레이티드 filed Critical 트렐리스 바이오싸이언스 인코포레이티드
Publication of KR20100091195A publication Critical patent/KR20100091195A/ko
Application granted granted Critical
Publication of KR101671452B1 publication Critical patent/KR101671452B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
KR1020107011433A 2007-10-25 2008-10-24 항rsv g 단백질 항체 Expired - Fee Related KR101671452B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US61/000,469 2007-10-25
US8940108P 2008-08-15 2008-08-15
US61/089,401 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (2)

Publication Number Publication Date
KR20100091195A KR20100091195A (ko) 2010-08-18
KR101671452B1 true KR101671452B1 (ko) 2016-11-17

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011433A Expired - Fee Related KR101671452B1 (ko) 2007-10-25 2008-10-24 항rsv g 단백질 항체

Country Status (14)

Country Link
US (3) US7736648B2 (cg-RX-API-DMAC7.html)
EP (1) EP2214711B1 (cg-RX-API-DMAC7.html)
JP (2) JP5808536B2 (cg-RX-API-DMAC7.html)
KR (1) KR101671452B1 (cg-RX-API-DMAC7.html)
CN (1) CN101808663B (cg-RX-API-DMAC7.html)
AU (1) AU2008316703B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0819210A2 (cg-RX-API-DMAC7.html)
CA (1) CA2703667C (cg-RX-API-DMAC7.html)
IL (1) IL205257A (cg-RX-API-DMAC7.html)
MX (1) MX2010004482A (cg-RX-API-DMAC7.html)
NZ (1) NZ585589A (cg-RX-API-DMAC7.html)
RU (1) RU2526517C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009055711A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003131B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv
EP2780366A2 (en) 2011-11-17 2014-09-24 AIMM Therapeutics B.V. Rsv g protein specific antibodies
HUE037186T2 (hu) * 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
AU2014255864B2 (en) * 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
WO2014170258A1 (en) * 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
WO2015120474A1 (en) * 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
DK3227339T3 (da) 2014-12-05 2022-01-10 Memorial Sloan Kettering Cancer Center Kimæriske antigenreceptorer rettet mod g-protein-koblet receptor og anvendelser deraf
AU2015357535B2 (en) 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
CN106496324B (zh) 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN105542003B (zh) * 2016-03-01 2019-12-06 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
EP3694548A4 (en) * 2017-10-13 2021-10-20 Trellis Bioscience, LLC CONFORMATIONAL EPITOPES IN THE CENTRAL PRESERVED REGION OF THE G PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
WO2020033742A1 (en) * 2018-08-08 2020-02-13 Trellis Bioscience, Llc Improved rsv passive and active vaccines
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Kmバイオロジクス株式会社 Rsv f/gキメラワクチン
EP4025513A4 (en) 2019-09-06 2023-10-04 Silgan White Cap LLC HINGED CLOSURE MEANS WITH A CLIP
WO2021053240A1 (en) * 2019-09-20 2021-03-25 Universiteit Antwerpen A novel human respiratory syncytial virus strain and its use
WO2021113780A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
WO2023081880A1 (en) 2021-11-08 2023-05-11 Silgan White Cap LLC Protrusion on container neck
JP2025527263A (ja) * 2022-08-02 2025-08-20 ノナ・バイオサイエンシズ(スーチョウ)カンパニー,リミテッド Msln抗体-薬物コンジュゲート
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160119C2 (ru) * 1993-05-25 2000-12-10 Американ Цианамид Компани Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
WO2000043040A1 (en) 1999-01-22 2000-07-27 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance p by using anti-substance p antibodies
EP1334119B2 (en) * 2000-10-18 2018-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for modulating rsv infection and immunity
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EP2041570A4 (en) 2006-07-12 2010-02-24 Trellis Bioscience Inc CellSpotTM APPLICATIONS
BRPI0819210A2 (pt) * 2007-10-25 2015-06-23 Trellis Bioscience Inc Anticorpos de proteína g anti-rsv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Also Published As

Publication number Publication date
CA2703667A1 (en) 2009-04-30
AU2008316703A1 (en) 2009-04-30
JP5808536B2 (ja) 2015-11-10
IL205257A0 (en) 2010-12-30
AU2008316703B2 (en) 2012-09-27
NZ585589A (en) 2012-07-27
EP2214711A2 (en) 2010-08-11
KR20100091195A (ko) 2010-08-18
WO2009055711A2 (en) 2009-04-30
AU2008316703A2 (en) 2010-07-22
ZA201003131B (en) 2011-03-30
EP2214711A4 (en) 2011-12-21
RU2010120879A (ru) 2011-11-27
MX2010004482A (es) 2010-07-06
BRPI0819210A2 (pt) 2015-06-23
US20130034564A1 (en) 2013-02-07
US8273354B2 (en) 2012-09-25
US9321830B2 (en) 2016-04-26
CN101808663A (zh) 2010-08-18
CN101808663B (zh) 2015-09-30
IL205257A (en) 2014-12-31
US20090130120A1 (en) 2009-05-21
JP2015078231A (ja) 2015-04-23
US7736648B2 (en) 2010-06-15
WO2009055711A3 (en) 2009-09-24
EP2214711B1 (en) 2018-08-15
JP2011500091A (ja) 2011-01-06
CA2703667C (en) 2015-12-29
RU2526517C2 (ru) 2014-08-20
US20100285022A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
CA2703667C (en) Anti-rsv g protein antibodies
EP2289550A2 (en) Ultra high affinity neutralizing antibodies
US20230174628A1 (en) Anti-novel coronavirus monoclonal antibody and application thereof
CN116785427B (zh) 呼吸道合胞病毒特异性结合分子的用途
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
RS50157B (sr) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična za rsv f-protein i postupci za njihovu proizvodnju
EA035846B1 (ru) Антитела человека, связывающиеся с g-белком rsv
KR20090088871A (ko) 인간 메타뉴모바이러스를 중화시키는 인간 항체
TW202306980A (zh) 一種呼吸道融合病毒的抗體及其應用
US9017668B2 (en) High affinity human antibodies to human cytomegalovirus (CMV) gB protein
KR20150135231A (ko) 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편
CN114174331A (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
US20220340658A1 (en) NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF
WO2023094980A1 (en) Antibodies to coronavirus
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
CN104628850B (zh) Rsv-特异性结合分子
WO2025022303A1 (en) Antibodies against covid-19 and other human coronaviruses
AU2006203015B2 (en) Ultra high affinity neutralizing antibodies
AU2012213962A1 (en) Ultra high affinity neutralizing antibodies
HK1154803A (en) Ultra high affinity neutralizing antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20251027

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20251027